Company profile
SIONNA THERAPEUTICS, INC.
NASDAQ:SIONBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07108153 | phase2 | completed | 2025-11-03 | 2026-06-25 | Sionna Therapeutics Inc. | Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta |
| NCT07035990 | phase1 | completed | 2025-07-23 | 2026-03-23 | Sionna Therapeutics Inc. | Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants. |
FDA applications (0)
No records yet.